Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Several other equities analysts have also recently weighed in on APTO. Alliance Global Partners upgraded Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. HC Wainwright lifted their target price on Aptose Biosciences from $2.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, March 28th.

Aptose Biosciences Price Performance

The firm has a 50 day moving average of $4.41 and a 200 day moving average of $7.37. Aptose Biosciences has a twelve month low of $1.35 and a twelve month high of $50.10. The company has a market capitalization of $3.66 million, a PE ratio of -0.58 and a beta of 1.04.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.